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Resveratrol has been reported to improve metabolic
function in metabolically abnormal rodents and
humans, but it has not been studied in nonobese
people with normal glucose tolerance. We conduct-
ed a randomized, double-blind, placebo-controlled
trial to evaluate the metabolic effects of 12 weeks
of resveratrol supplementation (75 mg/day) in non-
obese, postmenopausal women with normal glu-
cose tolerance. Although resveratrol supplemen-
tation increased plasma resveratrol concentration,
it did not change body composition, resting meta-
bolic rate, plasma lipids, or inflammatory markers.
A two-stage hyperinsulinemic-euglycemic clamp
procedure, in conjunction with stable isotopically
labeled tracer infusions, demonstrated that res-
veratrol did not increase liver, skeletal muscle, or
adipose tissue insulin sensitivity. Consistent with
the absence of in vivo metabolic effects, resveratrol
did not affect its putative molecular targets,
including AMPK, SIRT1, NAMPT, and PPARGC1A,
in either skeletal muscle or adipose tissue. These
findings demonstrate that resveratrol supplemen-
tation does not have beneficial metabolic effects
in nonobese, postmenopausal women with normal
glucose tolerance.
INTRODUCTION
Resveratrol, a naturally occurring polyphenol that is found
primarily in the skin of grapes, is purported to mimic the health
benefits of calorie restriction (CR) by improving metabolic func-
tion, reducing cancer risk, and ameliorating other age-related
pathology (Baur and Sinclair, 2006; Mercken et al., 2012). These658 Cell Metabolism 16, 658–664, November 7, 2012 ª2012 Elsevierpotential benefits have led to a marked growth in the purchase
of resveratrol supplements, with annual sales of $30 million in
the United States alone (http://newhope360.com/ingredients/
what-will-be-superstar-ingredients-2010/). Data from a series
of studies conducted in rodent models of diet-induced obesity
have shown that resveratrol increases insulin sensitivity, im-
proves glucose tolerance and plasma lipids, prevents the
development of fatty liver, enhances mitochondrial biogenesis,
suppresses inflammation and oxidative stress, and extends life
span (Baur et al., 2006; Lagouge et al., 2006; Sun et al., 2007;
Um et al., 2010). In contrast, resveratrol did not improve glucose
tolerance, insulin sensitivity, plasma lipid profile, or life span in
normal rodents (Jeon et al., 2012; Juan et al., 2002; Miller
et al., 2011; Strong et al., 2012; Turrens et al., 1997), but it did
mimic transcriptional changes induced by calorie restriction
(Barger et al., 2008a, 2008b; Pearson et al., 2008) and improved
several age-associated abnormalities in different organ systems
(Pearson et al., 2008).
Recently, it was reported that resveratrol improves insulin
sensitivity, postprandial plasma glucose concentration, and
mitochondrial function and decreases inflammation in adults
who are obese, have type 2 diabetes, or have impaired glucose
tolerance (Brasnyo´ et al., 2011; Crandall et al., 2012; Timmers
et al., 2011). However, it is not known whether resveratrol
supplementation has similar benefits in nonobese people who
have normal oral glucose tolerance, which has important impli-
cations for the general population.
The purpose of the present study was to conduct a random-
ized, double-blind, placebo-controlled trial to evaluate the
metabolic effects of resveratrol supplementation (75 mg/day,
99% pure trans-resveratrol [resVida from DSM Nutritional
Products] for 12 weeks) in lean and overweight women. To this
end, we determined the effect of resveratrol on insulin sensitivity
in vivo by using a two-stage hyperinsulinemic-euglycemic
clamp procedure, in conjunction with stable isotopically labeled
tracer infusions, and investigated global gene expression
and the key molecular events induced by resveratrol in adipose
tissue and skeletal muscle.Inc.
Table 1. Body Composition Before and After Placebo and Resveratrol Treatment
Placebo Resveratrol
Before After Before After
Body mass index (kg/m2) 24.3 ± 2.7 24.3 ± 2.7 24.2 ± 2.8 24.2 ± 2.9
Fat-free mass (kg) 40.6 ± 3.1 40.8 ± 2.9 42.4 ± 4.2 42.6 ± 3.9
Fat mass (% body weight) 36.0 ± 5.6 35.6 ± 5.8 35.7 ± 6.1 35.3 ± 6.6
Subcutaneous abdominal fat volume (cm3) 2,080 ± 794 2,065 ± 785 2,269 ± 785 2,287 ± 811
Intra-abdominal fat volume (cm3) 822 ± 526 811 ± 517 1,031 ± 550 1,077 ± 569
Intrahepatic triglyceride content (%) 2.85 ± 4.55 2.50 ± 3.39 2.61 ± 1.47 3.17 ± 2.41
Values are means ± SD. See also Table S2.
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Resveratrol Supplementation Was Well Tolerated
Subjects randomized to the resveratrol supplementation (n =
15; age, 58.2 ± 4.0 years) or placebo (n = 14; age, 59.8 ± 4.3
years) had similar baseline characteristics (Tables 1 and 2).
No adverse effects of resveratrol on standard blood tests or
electrocardiogram were detected (Table S1 and Supplemental
Experimental Procedures available online). Based on the
assessment of pill counts, all subjects took at least 80% of
the capsules with an average compliance of 92% in the
placebo group and 94% in the resveratrol group. To further
ensure that subjects were compliant with resveratrol supple-
mentation, we measured plasma resveratrol and dihydroresver-
atrol concentrations before and after 12 weeks of treatment.
Total resveratrol and dihydroresveratrol (free and conjugated
forms) were not detected in plasma in the resveratrol or
placebo groups at baseline but were present in plasma after
intervention in the resveratrol group only (Table 2). Total plasma
resveratrol concentration increased to a maximal concentration
of 992 ± 258 ng/ml at 2 hr after dosing and did not reach
baseline levels after 6 hr; the estimated half-life of elimination
was 6.5 hr (range: 3.5 hr to 11 hr).
Resveratrol Does Not Affect Body Composition,
Basal Metabolic Variables, or Insulin Sensitivity
After 12 weeks of resveratrol supplementation, body weight
and body composition (fat mass, fat-free mass [FFM], intra-
abdominal fat volume, and intrahepatic triglyceride content)
did not change (Table 1). Plasma substrates and hormones
(glucose, insulin, and plasma lipids), adipokines (adiponectin
and leptin), markers of inflammation (c-reactive protein [CRP]
and interleukin-6 [IL-6]), the homeostasis model assessment
of insulin resistance (HOMA-IR) score, blood pressure, heart
rate, and resting metabolic rate did not change after resveratrol
supplementation (Table 2). A hyperinsulinemic-euglycemic
clamp procedure was performed to more carefully assess
multiorgan insulin action. No effect of resveratrol supple-
mentation was detected in basal glucose or fatty acid kinetics
(Table 2) or insulin sensitivity in liver (hepatic insulin sensitivity
index and insulin-mediated suppression of glucose rate of
appearance [Ra] into plasma), adipose tissue (insulin-mediated
suppression of palmitate Ra), and skeletal muscle (insulin-
mediated stimulation of glucose rate of disappearance [Rd])
(Figure 1).Cell MResveratrol Supplementation Does Not Induce
Beneficial Molecular Adaptations
Data from studies conducted in animal models suggest the
beneficial effects of resveratrol are mediated by the pathways
involving AMP-activated protein kinase (AMPK), NAD+ bio-
synthesis, NAD+-dependent protein deacetylase SIRT1, and
peroxisome proliferator-activated receptor g coactivator-1a
(PPARGC1A), which stimulate mitochondrial biogenesis by
increasing key regulators such as uncoupling protein-3 (Ucp3)
(Baur et al., 2006; Lagouge et al., 2006; Park et al., 2012; Um
et al., 2010). Moreover, gene expression of SIRT1, nicotinamide
phosphoribosyltransferase (NAMPT; a key NAD+ biosynthetic
enzyme), PPARGC1A, and UCP3 are upregulated by resveratrol
(Ajmo et al., 2008; Lagouge et al., 2006; Mukherjee et al., 2009;
Um et al., 2010). Therefore, we measured gene expression of
these putative resveratrol targets in skeletal muscle and adipose
tissue in a subset of subjects in the placebo and resveratrol
groups, and we found the expression of these genes in both
skeletal muscle and adipose tissue were not affected by resver-
atrol supplementation (Figure 2A). To further examine global
transcriptional changes caused by resveratrol, we performed
microarray analyses of both skeletal muscle and adipose tissue
samples and conducted a gene set enrichment analysis (GSEA)
to identify the biological pathways that might be affected by
resveratrol. Resveratrol supplementation was associated with
a significant effect on only two pathways (KINESIN_COMPLEX,
false discovery rate [FDR] = 0.015; UBIQUITIN_LIGASE_
COMPLEX, FDR = 0.216) in skeletal muscle and did not have
any significant effects in adipose tissue. In contrast with data
from previous reports that found resveratrol affected the bio-
logical pathways linked to mitochondrial function and inflam-
mation in obese humans (Timmers et al., 2011) and rodents
(Lagouge et al., 2006), we did not detect any effect of resveratrol
on these pathways in either skeletal muscle or adipose tissue
(Figure 2B). Furthermore, resveratrol had no effect on the bio-
logical pathways related to AMPK (Figure 2B) and did not alter
the phosphorylation levels of AMPKa (Thr172) in skeletal muscle
(Figure 2C).
Moderate Weight Loss Induced by Short-Term
CR Changes Body Composition and Tissue
Gene Expression
Moderate weight loss induced by short-term CR decreased total
body fat mass, intra-abdominal adipose tissue volume, and in-
trahepatic triglyceride content but did not result in significantetabolism 16, 658–664, November 7, 2012 ª2012 Elsevier Inc. 659
Table 2. Plasma Resveratrol and Metabolic Variables Before and After Placebo and Resveratrol Treatment
Placebo Resveratrol
Before After Before After
Total resveratrol (ng/ml) ND ND ND 109.2 ± 185.0
Total dihydroresveratrol (ng/ml) ND ND ND 168.9 ± 106.0
Glucose (mg/dl) 94.2 ± 6.7 91.5 ± 6.2 94.8 ± 5.7 93.1 ± 5.5
Insulin (mU/liter) 4.9 ± 2.7 4.2 ± 2.0 5.9 ± 3.2 5.7 ± 3.1
HOMA-IR 1.17 ± 0.69 0.96 ± 0.48 1.41 ± 0.80 1.32 ± 0.75
Free fatty acids (mmol/liter) 0.62 ± 0.15 0.58 ± 0.10 0.67 ± 0.14 0.58 ± 0.15
Total cholesterol (mg/dl) 187 ± 30 186 ± 37 210 ± 35 197 ± 32
LDL cholesterol (mg/dl) 108 ± 27 109 ± 32 131 ± 33 120 ± 33
Triglyceride (mg/dl) 97 ± 58 93 ± 57 118 ± 42 118 ± 52
HDL cholesterol (mg/dl) 60 ± 13 58 ± 13 56 ± 10 54 ± 12
Adiponectin (mg/ml) 13.3 ± 4.8 13.4 ± 4.6 12.5 ± 5.6 12.0 ± 5.0
Leptin (ng/ml) 24.5 ± 17.4 22.4 ± 16.5 21.1 ± 13.1 20.4 ± 11.8
IL-6 (pg/ml) 2.08 ± 2.39 1.84 ± 1.68 1.58 ± 0.60 2.01 ± 1.98
CRP (ng/ml) 1.68 ± 1.64 1.51 ± 1.72 2.10 ± 2.33 2.78 ± 3.01
Resting metabolic rate (kcal/kg/day) 19.5 ± 2.5 19.0 ± 2.6 18.7 ± 2.5 17.7 ± 1.9
HISI (1,000/mmol/min 3 mU/ml) 0.41 ± 0.24 0.47 ± 0.23 0.37 ± 0.25 0.38 ± 0.24
Basal glucose Ra (mmol/kg FFM/min) 17.1 ± 2.9 15.8 ± 1.9 15.9 ± 2.0 15.5 ± 1.5
Basal palmitate Ra (mmol/kg FFM/min) 1.78 ± 0.50 1.75 ± 0.42 1.82 ± 0.41 1.64 ± 0.62
Systolic blood pressure (mm Hg) 123 ± 15 121 ± 14 118 ± 16 119 ± 16
Diastolic blood pressure (mm Hg) 65 ± 10 63 ± 9 67 ± 11 72 ± 10
Heart rate (beats/min) 68 ± 8 65 ± 10 66 ± 8 65 ± 7
Values are means ± SD. ND, not detectable; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; HDL,
high-density lipoprotein; HISI, hepatic insulin sensitivity index; FFM, fat-free mass. See also Table S2.
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consistent with the results obtained in previous weight loss
studies conducted in metabolically healthy obese people and
in postmenopausal women (Janiszewski and Ross, 2010; Jo-
seph et al., 2001; Karelis et al., 2008; Shin et al., 2006). Nonethe-
less, CR-induced moderate weight loss altered adipose tissue
gene expression profiles in several CR targets identified previ-
ously in human subjects, including upregulation of CTEP
(Johansson et al., 2012) and downregulation of LEP (Viguerie
et al., 2005), ALDOC (Capel et al., 2008; Johansson et al.,
2012; Ong et al., 2009), ABCC6 (Ong et al., 2009), and CCND2
(Kolehmainen et al., 2008) (Figure S1).
DISCUSSION
The use of resveratrol supplements to promote health has
become increasingly popular (Mercken et al., 2012). Data
from a series of studies conducted in obese, metabolically
abnormal rodent models have demonstrated that resveratrol
improves metabolic outcomes, particularly insulin sensitivity,
glucose tolerance, and plasma lipids (Baur et al., 2006;
Lagouge et al., 2006; Sun et al., 2007; Um et al., 2010). Further-
more, it was recently reported that resveratrol improves meta-
bolic outcomes in people who were either obese, had impaired
glucose tolerance or had type 2 diabetes (Brasnyo´ et al., 2011;
Crandall et al., 2012; Timmers et al., 2011). The present study
provides a comprehensive evaluation of the use of resveratrol
in nonobese women with normal glucose tolerance. Our find-660 Cell Metabolism 16, 658–664, November 7, 2012 ª2012 Elsevierings demonstrate that 12 weeks of resveratrol supplementation
(75 mg/day) increased plasma total resveratrol and total dihy-
droresveratrol concentrations but did not alter liver, skeletal
muscle, or adipose tissue insulin sensitivity and did not have
any effects on other key metabolic variables, such as body
composition, plasma lipids, plasma markers of inflammation,
or resting metabolic rate. Furthermore, resveratrol supple-
mentation did not affect its major putative molecular targets
in either adipose tissue or skeletal muscle, including SIRT1,
NAMPT, PPARGC1A, and UCP3 expression, AMPK phos-
phorylation, and biological pathways linked to mitochondrial
function or inflammation. These data show that resveratrol
supplementation (equivalent to the amount of resveratrol in-
gested by consuming 8 liters of red wine per day [Stark
et al., 2011]) in nonobese women with normal glucose tolerance
does not affect cellular signaling or result in metabolic benefits.
Three previous studies, conducted in different cohorts of
metabolically abnormal subjects, found 4 weeks of resveratrol
therapy, given at doses ranging from 10 mg to 2,000 mg per
day, resulted in several metabolic benefits, including an
improvement in insulin sensitivity (Brasnyo´ et al., 2011; Crandall
et al., 2012; Timmers et al., 2011), postprandial plasma glucose
concentrations (Crandall et al., 2012), and plasma lipid profile
(Timmers et al., 2011). However, the overall conclusions from
these studies are limited because the beneficial effects were
not consistent across studies and were not proportional to
resveratrol dose. For example, both low and moderate doses
(10 mg/day and 150 mg/day) (Brasnyo´ et al., 2011; TimmersInc.
Figure 1. Liver, Adipose Tissue, and Skel-
etal Muscle Insulin Sensitivity
Insulin-mediated suppression of glucose rate of
appearance (Ra) (A), insulin-mediated suppression
of palmitate Ra (B), insulin-mediated increase
in glucose rate of disappearance (Rd) (C), and
absolute glucose Rd values (D) before (white
bars) and after (black bars) placebo (n = 14) or
resveratrol (n = 15) supplementation. Values are
means ± SE. See also Table S2.
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Resveratrol and Metabolic Functionet al., 2011), but not high doses (1,000–2,000 mg/day) (Crandall
et al., 2012), of resveratrol reduced insulin resistance as
measured by HOMA-IR score, and 150 mg/day (Timmers et al.,
2011), but not 1,000–2,000 mg/day (Crandall et al., 2012), of
resveratrol decreased plasma triglyceride concentration.
If resveratrol supplementation is beneficial as reported, why
did we not detect any metabolic effects of resveratrol in our
subjects? It is unlikely that the lack of metabolic benefits is
simply due to differences in the dose or duration of resveratrol
supplementation. The dose of resveratrol given to our subjects
(75 mg/day for 12 weeks) was lower than the dose given in the
previous study involving obese subjects (150 mg/day for
30 days) (Timmers et al., 2011) or older subjects with impaired
glucose tolerance (1,000–2,000 mg/day for 4 weeks) (Crandall
et al., 2012) but much higher than the dose given in the study
involving subjects with diabetes (10 mg/day for 4 weeks) (Bras-
nyo´ et al., 2011). We are not able to determine the bioavailability
of resveratrol in some of these studies because different resver-
atrol compounds were used and plasma concentrations were
not reported (Brasnyo´ et al., 2011; Crandall et al., 2012). The
plasma concentrations of total resveratrol and total dihydrores-
veratrol in our subjects were 40%–50% lower than the plasma
concentrations reported in the study conducted in obese
subjects supplemented with 150 mg/day (Timmers et al.,
2011), which provided the same resveratrol compound used in
our study, but our plasma levels were likely higher than the
concentrations achieved in the study conducted in diabetic
subjects supplemented with 10 mg/day (Brasnyo´ et al., 2011).
Furthermore, the duration of resveratrol supplementation
in our subjects (12 weeks) was longer than the duration of
supplementation in the previous three studies (4 weeks). None-
theless, we cannot exclude the possibility that we were unableCell Metabolism 16, 658–664,to detect modest metabolic benefits
of resveratrol supplementation due to
the number of subjects in our study.
However, it seems unlikely that clinically
meaningful effects weremissed, because
the values for the key metabolic out-
comes after resveratrol supplementation
were nearly identical to values obtained
before supplementation.
We did not detect an effect of resvera-
trol supplementation on the gene ex-
pression profiles that are affected by
resveratrol in normal mice (Barger et al.,
2008a, 2008b; Pearson et al., 2008). In
contrast, we found that moderate weightloss induced significant changes in gene expression profiles in
adipose tissue and skeletal muscle, particularly genes that are
known as CR targets in adipose tissue, identified in previous
microarray studies conducted in human subjects (Capel et al.,
2008; Johansson et al., 2012; Kolehmainen et al., 2008; Ong
et al., 2009; Viguerie et al., 2005). However, data from several
studies conducted in rodent models have found many putative
resveratrol targets, such as SIRT1, NAMPT, and PPARGC1A,
are affected by fasting (Hayashida et al., 2010; Yang et al.,
2007; Yoon et al., 2001), so it is possible that collecting tissue
samples from our subjects after they fasted overnight (12 hr)
masked an effect induced by resveratrol on tissue gene
expression.
An important difference between the present study and those
conducted previously is that our subjects were nonobese
women with normal glucose tolerance, whereas the subjects in
the other studies had more severe pre-existing metabolic
dysfunction, such as obesity, type 2 diabetes, and impaired
glucose tolerance. Studies conducted in rodent models of diet-
induced obesity have shown that resveratrol improves insulin
sensitivity, lipids, and mitochondrial function (Baur et al., 2006;
Lagouge et al., 2006; Sun et al., 2007; Um et al., 2010) but
does not show beneficial metabolic effects in normal rodents
(Jeon et al., 2012; Juan et al., 2002; Miller et al., 2011; Strong
et al., 2012; Turrens et al., 1997). Therefore, it is possible that
resveratrol only improves metabolic outcomes in obese and
metabolically abnormal people, and not in nonobese glucose-
tolerant women.
In conclusion, we found that 12 weeks of resveratrol supple-
mentation (75 mg/day) does not affect its putative molecular
targets in skeletal muscle and adipose tissue or improve
metabolic function, including insulin sensitivity and plasmaNovember 7, 2012 ª2012 Elsevier Inc. 661
Figure 2. Assessment of Putative Resveratrol Molecular Targets
Relative gene expressions of SIRTt1, nicotinamide phosphoribosyltransferase (NAMPT), PPARGC1A, andUCP3 (means ± SE) determined by quantitative PCR in
skeletal muscle (upper panel) and adipose tissue (lower panel) before (white bars) and after (black bars) placebo or resveratrol supplementation (n = 8–12 per
group) (A). Microarray analyseswere performedwith skeletal muscle and adipose tissue biopsy samples. GSEAwas used to identify potential biological pathways
affected by resveratrol. Representative resveratrol target pathways related to mitochondrial function, inflammation, and AMPK are shown (B). The levels of
phosphorylated AMPKa (Thr172) and total AMPKa in skeletal muscle from four subjects before (white bars) and after (black bars) resveratrol supplementation
were determined by using western blotting (C). Values are means ± SE. See also Figure S1.
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These findings are consistent with data from studies conducted
in lean metabolically normal rodents. Additional randomized662 Cell Metabolism 16, 658–664, November 7, 2012 ª2012 Elseviercontrolled studies are still needed to assess the potential
benefits of resveratrol supplementation in metabolically ab-
normal individuals.Inc.
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Study Subjects
A total of 45 lean and overweight, Caucasian, postmenopausal women were
randomly assigned to one of three groups: (1) placebo treatment for 12 weeks
(n = 15), (2) resveratrol supplementation (75mg/day) for 12weeks (n = 15), or (3)
calorie restriction targeted to achieve a 5%weight losswithin 12weeks (n =15).
One subject who was randomized to the placebo group was dropped from
the study because of self-dieting and an 8.7% weight loss. All subjects
completed a comprehensive medical evaluation, including a detailed history,
physical examination, blood tests, a 12-lead electrocardiogram, and a 2 hr
oral glucose tolerance test. No subject had any history or evidence of
type 2 diabetes or cardiovascular disease, and no subject had a diagnosis or
was being treated for abnormal plasma lipids or hypertension. However, ten
subjects within the placebo and resveratrol groups had at least one feature of
themetabolic syndrome (HDL-cholesterol < 50mg/dl, triglyceride > 150mg/dl,
or increased blood pressure [systolic blood pressure R 135 mmHg or
diastolic blood pressure R 85 mmHg]). Subjects provided written informed
consent before participating in this study (ClinicalTrials.gov Identifier
NCT00823381), which was approved by the Institutional Review Board of
Washington University in St. Louis, MO.
Study Protocol
Body Composition
Body fat mass and FFM were determined by dual-energy X-ray absorptiome-
try, intra-abdominal and subcutaneous adipose tissue volumes were
quantified by using magnetic resonance imaging, and intrahepatic triglyceride




Subjects were admitted to the Clinical Research Unit at Washington University
School of Medicine in the afternoon on the day before the clamp procedure.
After subjects fasted for 12 hr overnight, a 9.5 hr, two-stage hyperinsuline-
mic-euglycemic clamp procedure, in conjunction with stable isotopically
labeled tracer infusion, was performed as previously described (Fabbrini
et al., 2009). Subcutaneous abdominal adipose tissue and skeletal muscle
(vastus lateralis) biopsies were obtained during the basal period of the clamp
procedure to investigate the molecular events induced by resveratrol treat-
ment. Resting metabolic rate was measured, via indirect calorimetry, during
the basal period of the clamp procedure.
Intervention and Postintervention Studies
After the baseline studies were completed, each subject was randomized to
12 weeks of treatment with resveratrol (75 mg/day; resVida 99.7% trans-
resveratrol, provided by DSM Nutritional Products, Kaiseraugst, Switzerland),
placebo, or calorie restriction with a three-block computer-generated
randomization scheme with a stratification of subjects based on a BMI value
<25 kg/m2 and R25 kg/m2. Subjects were instructed to take one capsule
(75 mg resveratrol or placebo) in the morning with breakfast. After 12 weeks
of supplementation, all studies performed at baseline were repeated. On the
day of the final clamp procedure, resveratrol was given in the morning and
blood samples were obtained before and at 30, 60, 90, 120, 240, 360 min
after resveratrol administration (before insulin infusion) to evaluate resveratrol
pharmacokinetics.
Sample Processing and Analyses
Details of analyses and calculations used to evaluate metabolic variables,
substrate kinetics, real-time PCR, microarray analyses, and western blot are
available in the Supplemental Experimental Procedures.
Statistical Analyses
The statistical significance of differences in postintervention outcome
measures between resveratrol and placebo treatment were evaluated by
analysis of covariance (ANCOVA) with the pretreatment values as the
covariates. Addition of the CR weight loss group to the analysis of out-
come measures did not change the comparisons between the placebo
and resveratrol groups. Results are presented as means ± SD, except in the
figures, which report data as means ± SE.Cell MACCESSION NUMBERS
All microarray data used in this study have been deposited into the NCBI GEO
database under accession number GSE41168.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
one figure, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2012.09.015.
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